EGFR and non-small cell lung carcinoma: Looking for molecular predictors of ICI efficacy, the pre-specified subgroup analysis of the 057 trial10 clearly showed that nivolumab did not improve neither PFS nor OS in patients with epidermal growth factor receptor (EGFR)-positive NSCLC.